Teva Pharmaceutical Industries Ltd (TEVA.N)
* Teva announces the launch of generic vagifem in the United States
TEL AVIV, July 23 Teva Pharmaceutical Industries said on Sunday it would lay off some of its 7,000 employees in Israel in the coming months as it reorganises in a drive to improve competitiveness.
BRUSSELS, July 17 EU antitrust regulators charged Israeli drugmaker Teva on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug, putting it at risk of a fine.
* Said on Monday it does not believe it entered into "any anti-competitive behavior" with Cephalon.
BRUSSELS, July 17 EU antitrust regulators charged Israeli drugmaker Teva on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's blockbuster sleep disorder drug.
(The following statement was released by the rating agency) SINGAPORE/MUMBAI, July 14 (Fitch) Fitch Ratings has revised Glenmark Pharmaceuticals Ltd's (Glenmark's) Outlook to Stable from Positive, and affirmed the Long-Term Issuer Default Rating (IDR) at 'BB'. The agency also affirmed the rating on Glenmark's USD200 million 4.50% senior unsecured notes due 2021 at 'BB'. The revision in the Outlook reflects Fitch's expectation that Glenmark's free cash flow will be largely neutral over the next t
TEL AVIV, July 12 Israel-based Teva Pharmaceutical Industries is expected to name Anglo-Swedish group AstraZeneca's Chief Executive Pascal Soriot as Teva's next CEO, the Calcalist financial news website said on Wednesday.
TEL AVIV, July 12 Israel-based Teva Pharmaceutical Industries will name AstraZeneca chief executive Pascal Soriot as its next CEO, the Calcalist financial news website said on Wednesday.
* Celltrion and teva announce u.s. Fda acceptance of biologics license application for proposed biosimilar to rituxan® (rituximab)
* Publication of AIM-TD study results in lancet psychiatry for investigational use of deutetrabenazine in tardive dyskinesia Source text for Eikon: Further company coverage: